RESUMO
An understanding of electrochemical dynamics at solid-liquid interfaces is essential to develop advanced batteries and fuel cells and so on. For example, an atomic-level understanding of electrochemical Pt dissolution and redeposition behavior is crucial for optimizing the material design and operating conditions of polymer electrolyte fuel cells (PEFCs). This understanding enables the prevention of the degradation of Pt nanoparticles used as electrocatalysts. However, the mechanisms of Pt dissolution and redeposition are still not fully understood due to the lack of spatial resolution available with current observation techniques. Here, we have revealed for the first time atomic-level electrochemical Pt dissolution and redeposition behavior using in-house-developed observation techniques. We achieved atomic-level observations of closed-cell type liquid electrochemical transmission electron microscopy (TEM) by combining in-house-developed microelectromechanical system (MEMS) chips as an electrochemical cell, an aberration-corrected TEM apparatus, and an energy filter. Furthermore, accurate and stable potential control was achieved using an in-house-developed reversible hydrogen electrode (RHE) with a liquid junction connected to the outside of a TEM specimen holder. Our observation results confirmed that Pt dissolves from surface step edges layer-by-layer, as previously predicted by the density functional theory (DFT). The observation techniques developed are also applicable to other research fields concerning electrochemistry.
RESUMO
Tissue factor pathway inhibitor (TFPI) is an anticoagulant protease inhibitor that inhibits the tissue factor-initiated blood coagulation cascade reactions. Based on these anticoagulant functions of TFPI, we hypothesized that genetic variations in TFPI may alter the TFPI expression or impair the anticoagulant function and could predispose persons to deep vein thrombosis (DVT). This study was undertaken to examine whether the genetic polymorphisms in TFPI are associated with the plasma TFPI levels and risk for DVT. We sequenced the entire coding regions of TFPI in 175 Japanese DVT patients and identified 12 genetic variants, including one missense mutation, Asn221Ser. The missense mutation occurred at the site presumably attached to the glycosylphosphatidylinositol anchor in the TFPI-beta form. The allele frequency of the mutant Ser-coding allele of the Asn221Ser mutation was 8% in the Japanese general population consisting of 1684 individuals. The Asn221Ser mutation was significantly associated with the total TFPI levels (Asn/Asn, n = 108, total TFPI = 56.57 +/- 0.88 ng/ml (mean +/- SD) vs. Asn/Ser + Ser/Ser, n = 16, total TFPI = 63.44 +/- 2.28 ng/ml, P = 0.0058). The genotype was not associated with the free TFPI level. This Asn221Ser mutation was not associated with DVT. Thus, the Asn221Ser mutation occurring in the TFPI-beta form was associated with the total TFPI level, but not a risk for DVT. The absence of the putative glycosylphosphatidylinositol anchor in TFPI-beta under pathological conditions remains to be studied.
Assuntos
Lipoproteínas/sangue , Lipoproteínas/genética , Mutação de Sentido Incorreto/genética , Alelos , Feminino , Variação Genética/genética , Genótipo , Humanos , Japão , Masculino , Polimorfismo de Nucleotídeo Único/genética , Trombose Venosa/sangue , Trombose Venosa/genéticaRESUMO
In this study, we investigate whether the combination of HVJ-AVE liposome-mediated TFPI gene transfer and recombinant TFPI (rTFPI) irrigation would reduce restenosis safely and more effectively. The results indicated that at 4 weeks after angioplasty, the MLD, EELA, IELA and LA of TFPI group and rTFPI group were markedly greater than those of the control groups, and those in the combination group were even greater. The mean IA, I/M, and the percentage of stenosis in TFPI gene group and rTFPI group were significantly reduced compared with control groups, and those in the combination group were even further reduced. Thrombosis in the TFPI gene group, rTFPI group and combination group was significantly reduced compared with the other control groups. The systemic coagulation status of treated animals was not significantly changed and no toxicity was observed in each group. So combination of TFPI gene transfer using HVJ-AVE liposomes and rTFPI irrigation could inhibit thrombosis and neointimal hyperplasia, and attenuate vascular remodeling and luminal stenosis more effectively than using each method alone. The combination method may be a more effective and safe strategy for the prevention of restenosis after angioplasty in humans.
Assuntos
Doença da Artéria Coronariana/terapia , Reestenose Coronária/terapia , Terapia Genética/métodos , Lipoproteínas/genética , Lipoproteínas/farmacologia , Animais , Terapia Combinada , Modelos Animais de Doenças , Lipossomos/farmacologia , Masculino , Coelhos , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacologia , Irrigação TerapêuticaRESUMO
This study assessed markers of vascular endothelial cell dysfunction associated with early atherosclerosis in carotid arteries. We measured the plasma levels of free-form tissue factor pathway inhibitor (free TFPI), plasminogen activator inhibitor-1 (PAI-1), and von Willebrand factor (vWF) in 522 adults without cardiovascular disease enrolled in the Suita Study. For each sex, we analyzed the association of the degree of intimal-medial thickness (IMT) with hemostatic markers using logistic regression analysis considering potential confounding risk factors, including age, body mass index, lifestyle (current smoking and drinking), illness (diabetes mellitus and hyperlipidemia), systolic blood pressure, and antihypertensive drug use. The age-adjusted levels of free TFPI and PAI-1 were positively and independently associated with the degree of IMT for men. Even after adjustment for all confounding factors, the level of PAI-1 was positively associated with the degree of IMT. These results indicate that measurement of the levels of free TFPI and PAI-1 is a potentially useful tool for the detection of early atherosclerosis in men.
Assuntos
Anticoagulantes/sangue , Arteriosclerose/diagnóstico , Arteriosclerose/fisiopatologia , Biomarcadores/análise , Doenças das Artérias Carótidas/fisiopatologia , Inibidor 1 de Ativador de Plasminogênio/sangue , Inibidores de Serina Proteinase/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Endotélio Vascular/citologia , Endotélio Vascular/patologia , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Valores de Referência , Túnica Íntima/patologiaRESUMO
BEta(2)-glycoprotein I (beta(2)-GPI) is proteolytically cleaved by plasmin in domain V (nicked beta(2)-GPI), being unable to bind to phospholipids. This cleavage may occur in vivo and elevated plasma levels of nicked beta(2)-GPI were detected in patients with massive plasmin generation and fibrinolysis turnover. In this study, we report higher prevalence of elevated ratio of nicked beta(2)-GPI against total beta(2)-GPI in patients with ischemic stroke (63%) and healthy subjects with lacunar infarct (27%) when compared to healthy subjects with normal findings on magnetic resonance imaging (8%), suggesting that nicked beta(2)-GPI might have a physiologic role beyond that of its parent molecule in patients with thrombosis. Several inhibitors of extrinsic fibrinolysis are known, but a negative feedback regulator has not been yet documented. We demonstrate that nicked beta(2)-GPI binds to Glu-plasminogen with K(D) of 0.37 x 10(-6) M, presumably mediated by the interaction between the fifth domain of nicked beta(2)-GPI and the fifth kringle domain of Glu-plasminogen. Nicked beta(2)-GPI also suppressed plasmin generation up to 70% in the presence of tissue plasminogen activator, plasminogen, and fibrin. Intact beta(2)-GPI lacks these properties. These data suggest that beta(2)-GPI/plasmin-nicked beta(2)-GPI controls extrinsic fibrinolysis via a negative feedback pathway loop.
Assuntos
Infarto Cerebral/etiologia , Retroalimentação Fisiológica , Fibrinólise , Glicoproteínas/metabolismo , Glicoproteínas/fisiologia , Idoso , Biomarcadores/sangue , Estudos de Casos e Controles , Infarto Cerebral/sangue , Feminino , Fibrinolisina/antagonistas & inibidores , Fibrinolisina/metabolismo , Glicoproteínas/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Plasminogênio/metabolismo , Ligação Proteica , Trombose/sangue , Trombose/etiologia , beta 2-Glicoproteína IRESUMO
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that regulates tissue factor-triggered blood coagulation. It has previously been reported that TFPI inhibits the proliferation of human umbilical vein endothelial cells (HUVECs), suggesting that TFPI may act as more than just a mediator of coagulation through changes in gene expression. By using DNA-array techniques and Northern blot analysis, we here revealed that TFPI transiently induced the mRNA expression of JUNB and GADD45B. The inducible effects were not observed in TFPIdeltaC (lacking the C-terminal basic region) or antithrombin (heparin-binding anticoagulant protease inhibitor). Moreover, the TFPI-induced expression of GADD45B was blocked by receptor-associated protein, which masks the ligand-binding domain of very low density lipoprotein receptor (VLDL-R). In conclusion, this is the first report to show an effect of TFPI on mRNA expression, and suggests that TFPI modulates cellular functions by inducing JUNB and GADD45B expression through binding to VLDL-R.
Assuntos
Antígenos de Diferenciação/genética , Lipoproteínas/farmacologia , Proteínas Proto-Oncogênicas c-jun/genética , RNA Mensageiro/biossíntese , Antígenos de Diferenciação/biossíntese , Northern Blotting , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Perfilação da Expressão Gênica , Regulação da Expressão Gênica , Humanos , Proteína Associada a Proteínas Relacionadas a Receptor de LDL/farmacologia , Análise de Sequência com Séries de Oligonucleotídeos , Proteínas Proto-Oncogênicas c-jun/biossíntese , Regulação para CimaRESUMO
To clarify the mechanism of interaction between chaperonin GroEL and substrate proteins, we studied the conformational changes; of the fifth domain of human beta(2)-glycoprotein I upon binding to GroEL. The fifth domain has a large flexible loop, containing several hydrophobic residues surrounded by positively charged residues, which has been proposed to be responsible for the binding of beta(2)-glycoprotein I to negatively charged phospholipid membranes. The reduction by dithiothreitol of the three intramolecular disulfide bonds of the fifth domain was accelerated in the presence of stoichiometric amounts of GroEL, indicating that the fifth domain was destabilized upon interaction with GroEL. To clarify the GroEL-induced destabilization at the atomic level, we performed H/(2)H exchange of amide protons using heteronuclear NMR spectroscopy. The presence of GroEL promoted the H/(2)H exchange of most of the protected amide protons, suggesting that, although the flexible loop of the fifth domain is likely to be responsible for the initiation of binding to GroEL, the interaction with GroEL destabilizes the overall conformation of the fifth domain.
Assuntos
Membrana Celular/metabolismo , Chaperonina 60/metabolismo , Glicoproteínas/química , Glicoproteínas/metabolismo , Sequência de Aminoácidos , Chaperonina 60/química , Dissulfetos/metabolismo , Fluorescência , Humanos , Hidrogênio/metabolismo , Espectroscopia de Ressonância Magnética , Proteínas de Membrana/química , Proteínas de Membrana/metabolismo , Modelos Moleculares , Dados de Sequência Molecular , Oxirredução , Ligação Proteica , Estrutura Terciária de Proteína , Prótons , Triptofano/metabolismo , beta 2-Glicoproteína IRESUMO
OBJECTIVE: Tissue factor pathway inhibitor (TFPI), as a primary inhibitor of TF-induced coagulation, reduces neointimal formation and luminal stenosis by inhibiting coagulation and thrombosis after vessel wall injury. Here, we investigated the effect of TFPI gene delivery with a HVJ-AVE liposome vector on restenosis in atherosclerotic arteries after angioplasty in rabbits. We also evaluated the safety of the novel gene therapeutic strategy to prevent restenosis. METHODS: Local iliac artery atherosclerosis was induced by a combination of balloon denudation and high-cholesterol diet in Japanese white rabbits, which were then subjected to angioplasty. Infusion of an HVJ-AVE liposome containing the TFPI gene or an "empty" pcDNA 3.1 expression vector, or HVJ-liposome vector only, or saline was performed at the site of angioplasty using a Dispatch((R)) catheter. Quantitative angiography and histopathology were performed before and after gene delivery and at 4 weeks follow-up. The safety of the gene therapy was evaluated over a 6-month observation period. RESULTS: TFPI mRNA and protein were detected in local TFPI gene transferred vessels after gene transfer. The mean minimal luminal diameter of the TFPI group was markedly greater than that of the control groups (P<0.01) at 4 weeks after gene transfer. The mean neointimal area, the ratio of the neointimal to medial areas, and percent of stenosis in the TFPI group were all significantly reduced compared with the control groups (each P<0.01). The external elastic luminal area, internal elastic luminal area, and luminal area were larger in the TFPI groups versus controls (each P<0.01). Thrombosis was found in five empty plasmid control group animals, but in only one in the TFPI group (P=0.05). The systemic coagulation status of the treated animals were not significantly changed in either the TFPI group or the control groups; no toxicity was observed after HVJ-AVE liposome-mediated TFPI gene transfer. CONCLUSIONS: HVJ-AVE liposome-mediated TFPI gene transfer significantly reduced neointimal hyperplasia, inhibited thrombosis, and attenuated vascular remodeling and lumimal stenosis after angioplasty in atherosclerotic arteries without any significant adverse effects.
Assuntos
Arteriosclerose/terapia , Técnicas de Transferência de Genes , Terapia Genética/métodos , Artéria Ilíaca , Lipoproteínas/genética , Angioplastia com Balão , Animais , Arteriosclerose/diagnóstico por imagem , Arteriosclerose/prevenção & controle , Expressão Gênica , Vetores Genéticos , Artéria Ilíaca/diagnóstico por imagem , Artéria Ilíaca/patologia , Lipoproteínas/metabolismo , Lipossomos , Masculino , RNA Mensageiro/genética , Coelhos , Radiografia , Recidiva , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
BACKGROUND: Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. METHODS: The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon. First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 microg of rTFPI given at 40 microg per pulse per minute by means of a Pulse Spray catheter. Thereafter, 34 rabbits which had received 200 microg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. RESULTS: A total of 2.6+/-1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. CONCLUSIONS: Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.
Assuntos
Angioplastia com Balão , Anti-Inflamatórios/uso terapêutico , Fibrinolíticos/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Ativador de Plasminogênio Tecidual/uso terapêutico , Animais , Anti-Inflamatórios/administração & dosagem , Cateterismo , Divisão Celular/efeitos dos fármacos , Cricetinae , Cricetulus , Desenho de Equipamento , Humanos , Artéria Ilíaca/efeitos dos fármacos , Artéria Ilíaca/patologia , Macrófagos/patologia , Coelhos , Proteínas Recombinantes/administração & dosagem , Trombose/prevenção & controle , Ativador de Plasminogênio Tecidual/administração & dosagem , Túnica Íntima/efeitos dos fármacos , Túnica Íntima/patologiaRESUMO
Tissue factor pathway inhibitor (TFPI) is a heparin-binding protein involved in the extrinsic blood coagulation system. In order to elucidate the minimal size of heparin chain required for the interaction with TFPI, we prepared a series of heparin-derived oligosaccharides with tailored chain length ranged from disaccharide to eicosasaccharide after the successive treatments of heparin, including partial N-desulphation, deaminative cleavage with nitrous acid and gel-filtration. Affinity chromatography study of each oligosaccharide fraction using TFPI as the ligand indicated that increasing the degree of polymerisation causes increased affinity, and that a remarkable change in the affinity occurs between the decamers and dodecamers. Measurement of factor Xa inhibitory activity of TFPI in the presence of each oligosaccharide fraction indicated that the fractions shorter than dodecamers only slightly enhanced the TFPI activity for factor Xa inhibition, while the fractions larger than octadecamers had an effect comparable to full-length heparin. These were compatible to the results from the kinetic analyses of the interaction between TFPI and heparin-derived oligosaccharide with an evanescent wave-based biosensor system, IAsys, using a TFPI C-terminal peptide as the ligand.
Assuntos
Heparina/química , Heparina/metabolismo , Lipoproteínas/metabolismo , Oligossacarídeos/isolamento & purificação , Sequência de Aminoácidos , Técnicas Biossensoriais , Cromatografia de Afinidade , Inibidores do Fator Xa , Lipoproteínas/química , Lipoproteínas/farmacologia , Dados de Sequência Molecular , Oligossacarídeos/metabolismo , Relação Estrutura-AtividadeRESUMO
We identified genes that were differentially expressed between spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) using cDNA microarray analysis, and analyzed the correlation between these genes and hypertension. Twenty four genes were found to be up-regulated and 20 were down-regulated in SHR. We selected 11 genes (6 up-regulated genes: SAH, Hsp70, MCT1, RBP, IDI1, Prion; and 5 down-regulated genes: Thrombin, Dyn, SOD3, Ela1, Gst Y(b)) and subjected them to an F2 cosegregation analysis. One hundred five F2 rats were obtained from the same strains used for microarray analysis, and blood pressure was measured directly with a catheter implanted in the femoral artery. The genotypes of monocarboxylate transporter 1 and glutathione S-transferase Y(b) subunit significantly affected diastolic blood pressure in F2 rats, and these two genes are located near each other on chromosome 2. However, quantitative trait loci (QTL) analysis in this region revealed that the QTL for diastolic blood pressure were from these two genes. Antihypertensive treatment with either enalapril or hydralazine only affected the expression level of Hsp70, which was up-regulated by hydralazine, probably through compensatory sympathetic activation. We were unable to associate the other 10 genes with hypertension in SHR. Based on these results, the identification of differentially expressed genes may not be an efficient method for selecting candidate genes for hypertension in the SHR-WKY system.
Assuntos
Expressão Gênica , Hipertensão/genética , Análise de Sequência com Séries de Oligonucleotídeos , Ratos Endogâmicos SHR/genética , Animais , Anti-Hipertensivos/uso terapêutico , Mapeamento Cromossômico , Hipertensão/tratamento farmacológico , Polimorfismo Genético , Locos de Características Quantitativas , Ratos , Ratos Endogâmicos WKYRESUMO
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor that inhibits the initial reactions of blood coagulation. A major pool of TFPI is the form associated with the surface of endothelial cells, which is speculated to play an important role in regulating the functions of vascular wall cells. TFPI consists of 3 tandem Kunitz inhibitor domains, the first and second of which inhibit the tissue factor-factor VIIa complex and factor Xa, respectively. Recent findings indicate that TFPI has another function, ie, the modulation of cell proliferation. This function is based on the interaction of the C-terminal region of TFPI with these cells. In addition to endothelial cells, it has been shown that many other vascular wall cells can synthesize TFPI, eg, mesangial cells, smooth muscle cells, monocytes, fibroblasts, and cardiomyocytes. TFPI is associated with these cells mainly through heparan sulfate proteoglycans on their surface. However, recent findings suggest that there are several other candidates for TFPI-binding proteins on these cells. On the other hand, studies on plasma levels of TFPI in patients with various diseases suggest that TFPI may be a marker of endothelial cell dysfunction. An increasing number of reports suggest that recombinant TFPI may attenuate thrombosis and prevent restenosis. Clinical trials are needed to explore these possibilities. Recent reports also indicate that the application of recombinant TFPI or TFPI gene transfer prevents restenosis in addition to thrombosis after arterial injury in the animal model; corroboration of these reports awaits clinical investigation.
Assuntos
Coagulação Sanguínea/fisiologia , Endotélio Vascular/fisiologia , Lipoproteínas/fisiologia , Animais , Arteriosclerose/etiologia , Biomarcadores/sangue , Divisão Celular , Endotélio Vascular/citologia , Fator VIIa/fisiologia , Inibidores do Fator Xa , Humanos , Lipoproteínas/química , Lipoproteínas/uso terapêutico , Camundongos , Camundongos Knockout , Estrutura Terciária de Proteína , Proteínas Recombinantes/uso terapêutico , Trombose/sangue , Trombose/prevenção & controleRESUMO
Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factor VIIa and Xa through its K1 and K2 domain, respectively, and the inhibitory activity is enhanced by heparin. The function of the K3 domain of TFPI has not been established, but the domain probably harbors a heparin binding site (HBS-2). We determined the three-dimensional solution structure of the TFPI K3 domain (Glu182-Gly242) by heteronuclear multidimensional NMR. The results showed that the molecule is composed of one antiparallel beta-sheet and one alpha-helix, and in overall structure is very similar to the K2 domain, with the rms deviation of 1.55 A for the 58 defined C(alpha) positions. However, the surface electrostatic properties of both domains are different each other. The lack of inhibitory activity of the K3 domain is explained by the absence of electrostatic interaction with factor Xa over a large surface area. A titration experiment with size-fractionated heparin showed that a heparin binding site was located in the vicinity of the alpha-helix. In this region, a positively charged cluster is formed by Lys213, Lys232, and Lys240, and the negatively charged sulfate groups of heparin bind there. The enhancement of inhibitory activity by heparin probably was not due to a conformational change to TFPI itself. It is likely that heparin simply increases the local concentration of TFPI on the cell surface and stabilizes the initial complex that forms.
Assuntos
Anticoagulantes/metabolismo , Heparina/metabolismo , Lipoproteínas/química , Lipoproteínas/metabolismo , Sequência de Aminoácidos , Aprotinina/química , Aprotinina/isolamento & purificação , Aprotinina/metabolismo , Sítios de Ligação , Primers do DNA/química , Inibidores do Fator Xa , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Ressonância Magnética Nuclear Biomolecular , Oligossacarídeos/química , Reação em Cadeia da Polimerase , Ligação Proteica , Conformação Proteica , Proteínas Recombinantes/química , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/metabolismoRESUMO
beta(2)-Glycoprotein I (beta(2)-GPI) is a plasma protein that binds to negatively charged substances such as DNA, heparin, and anionic phospholipids. The interaction of beta(2)-GPI with anionic phospholipids is intriguing in the context of the autoimmune disease antiphospholipid syndrome. To extend understanding of the binding mechanism to phospholipids, the interactions of beta(2)-GPI with amphiphiles, i.e., sodium lauryl sulfate and lysophospholipids, were examined. These amphiphiles induced the aggregation of beta(2)-GPI below the critical micelle concentration, indicating that the interaction of beta(2)-GPI with monodispersed amphiphiles is unstable, resulting in the formation of large aggregates. However, highly soluble monocaproylphosphatidic acid did not induce aggregation, suggesting that the hydrophobicity of the acyl chain is also an important factor for aggregate formation in addition to negative charges in the headgroup. A series of experiments using deletion mutants and a peptide showed that the fifth domain of beta(2)-GPI (domain V) is responsible for formation of aggregates observed for intact full-length beta(2)-GPI. In addition, the flexible loop (F307-C326) in the C-terminal of domain V, which consists of hydrophobic and positively charged residues, was identified as the important region for aggregation. These results indicate that beta(2)-GPI binds to the amphiphiles through the flexible loop of domain V, resulting in formation of large aggregates where both electrostatic and hydrophobic interactions are involved.